• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过一级风险因素改变预防子宫内膜癌的理论潜力:来自 EPIC 队列的估计。

Theoretical potential for endometrial cancer prevention through primary risk factor modification: Estimates from the EPIC cohort.

机构信息

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Nutrition and Metabolism Section, International Agency for Research on Cancer (IARC), Lyon, France.

出版信息

Int J Cancer. 2020 Sep 1;147(5):1325-1333. doi: 10.1002/ijc.32901. Epub 2020 Feb 18.

DOI:10.1002/ijc.32901
PMID:32011733
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8611794/
Abstract

Endometrial cancer (EC) incidence rates vary ~10-fold worldwide, in part due to variation in EC risk factor profiles. Using an EC risk model previously developed in the European EPIC cohort, we evaluated the prevention potential of modified EC risk factor patterns and whether differences in EC incidence between a European population and low-risk countries can be explained by differences in these patterns. Predicted EC incidence rates were estimated over 10 years of follow-up for the cohort before and after modifying risk factor profiles. Risk factors considered were: body mass index (BMI, kg/m ), use of postmenopausal hormone therapy (HT) and oral contraceptives (OC) (potentially modifiable); and, parity, ages at first birth, menarche and menopause (environmentally conditioned, but not readily modifiable). Modeled alterations in BMI (to all ≤23 kg/m ) and HT use (to all non-HT users) profiles resulted in a 30% reduction in predicted EC incidence rates; individually, longer duration of OC use (to all ≥10 years) resulted in a 42.5% reduction. Modeled changes in not readily modifiable exposures (i.e., those not contributing to prevention potential) resulted in ≤24.6% reduction in predicted EC incidence. Women in the lowest decile of a risk score based on the evaluated exposures had risk similar to a low risk countries; however, this was driven by relatively long use of OCs (median = 23 years). Our findings support avoidance of overweight BMI and of HT use as prevention strategies for EC in a European population; OC use must be considered in the context of benefits and risks.

摘要

子宫内膜癌 (EC) 的发病率在全球范围内差异约为 10 倍,部分原因是 EC 风险因素谱的差异。我们使用之前在欧洲 EPIC 队列中开发的 EC 风险模型,评估了修改后的 EC 风险因素模式的预防潜力,以及欧洲人群与低风险国家之间的 EC 发病率差异是否可以用这些模式的差异来解释。在修改风险因素谱之前和之后,我们为队列计算了 10 年随访期间的 EC 预测发病率。考虑的风险因素有:体重指数(BMI,kg/m )、绝经后激素治疗(HT)和口服避孕药(OC)的使用(潜在可修改);以及生育次数、首次分娩年龄、初潮和绝经年龄(环境条件,但不易修改)。模拟的 BMI(全部≤23 kg/m )和 HT 使用(全部非 HT 用户)谱的改变导致预测 EC 发病率降低 30%;单独使用 OC 的时间更长(全部≥10 年)导致发病率降低 42.5%。不易修改的暴露(即,对预防潜力没有贡献的暴露)的模拟变化导致预测 EC 发病率降低≤24.6%。根据评估的暴露因素,风险评分最低十分位数的女性的风险与低风险国家相似;然而,这是由于相对较长时间使用 OC(中位数=23 年)所致。我们的研究结果支持在欧洲人群中避免超重 BMI 和 HT 使用作为 EC 的预防策略;必须根据获益和风险来考虑 OC 的使用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98e2/8611794/de00a1eefc95/IJC-147-1325-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98e2/8611794/de00a1eefc95/IJC-147-1325-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98e2/8611794/de00a1eefc95/IJC-147-1325-g001.jpg

相似文献

1
Theoretical potential for endometrial cancer prevention through primary risk factor modification: Estimates from the EPIC cohort.通过一级风险因素改变预防子宫内膜癌的理论潜力:来自 EPIC 队列的估计。
Int J Cancer. 2020 Sep 1;147(5):1325-1333. doi: 10.1002/ijc.32901. Epub 2020 Feb 18.
2
Worldwide variations in the lifetime probability of reproductive cancer in women: implications of best-case, worst-case, and likely-case assumptions about the effect of oral contraceptive use.全球女性生殖系统癌症终生发病概率的差异:关于口服避孕药使用效果的最佳情况、最差情况及可能情况假设的影响
Contraception. 1992 Feb;45(2):93-104. doi: 10.1016/0010-7824(92)90043-s.
3
An epidemiological model for prediction of endometrial cancer risk in Europe.用于预测欧洲子宫内膜癌风险的流行病学模型。
Eur J Epidemiol. 2016 Jan;31(1):51-60. doi: 10.1007/s10654-015-0030-9. Epub 2015 May 13.
4
Modification of the Associations Between Duration of Oral Contraceptive Use and Ovarian, Endometrial, Breast, and Colorectal Cancers.口服避孕药使用时间与卵巢癌、子宫内膜癌、乳腺癌和结直肠癌相关性的改变。
JAMA Oncol. 2018 Apr 1;4(4):516-521. doi: 10.1001/jamaoncol.2017.4942.
5
The preventable burden of endometrial and ovarian cancers in Australia: A pooled cohort study.澳大利亚可预防的子宫内膜癌和卵巢癌负担:一项汇总队列研究。
Gynecol Oncol. 2019 Jun;153(3):580-588. doi: 10.1016/j.ygyno.2019.03.102. Epub 2019 Mar 29.
6
Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition.生殖风险因素与子宫内膜癌:欧洲癌症与营养前瞻性调查研究。
Int J Cancer. 2010 Jul 15;127(2):442-51. doi: 10.1002/ijc.25050.
7
Endometrial cancer incidence trends in Europe: underlying determinants and prospects for prevention.欧洲子宫内膜癌发病率趋势:潜在决定因素及预防前景
Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1132-42. doi: 10.1158/1055-9965.EPI-04-0871.
8
Incidence and factors associated with synchronous ovarian and endometrial cancer: a population-based case-control study.卵巢和子宫内膜癌同时发生的发病率及相关因素:一项基于人群的病例对照研究。
Gynecol Oncol. 2012 Apr;125(1):109-13. doi: 10.1016/j.ygyno.2011.12.444. Epub 2011 Dec 28.
9
Risk factors for endometrial cancer in black and white women: a pooled analysis from the Epidemiology of Endometrial Cancer Consortium (E2C2).黑人和白人女性子宫内膜癌的危险因素:来自子宫内膜癌流行病学联盟(E2C2)的汇总分析。
Cancer Causes Control. 2015 Feb;26(2):287-296. doi: 10.1007/s10552-014-0510-3. Epub 2014 Dec 23.
10
Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' Oral Contraception Study.终生癌症风险与口服避孕药:皇家全科医生学院口服避孕药研究。
Am J Obstet Gynecol. 2017 Jun;216(6):580.e1-580.e9. doi: 10.1016/j.ajog.2017.02.002. Epub 2017 Feb 8.

引用本文的文献

1
Association of oral contraceptives and risk of endometrial cancer: A systematic review and meta-analysis.口服避孕药与子宫内膜癌风险的关联:一项系统评价与荟萃分析。
Acta Obstet Gynecol Scand. 2025 Apr;104(4):591-603. doi: 10.1111/aogs.15043. Epub 2025 Feb 21.
2
Recent Advances in Endometrial Cancer Prevention, Early Diagnosis and Treatment.子宫内膜癌预防、早期诊断与治疗的最新进展
Cancers (Basel). 2024 Mar 1;16(5):1028. doi: 10.3390/cancers16051028.
3
Diane-35 and metformin therapy in rats with endometrial lesions induced by dihydrotestosterone exposure.

本文引用的文献

1
Contemporary Hormonal Contraception and the Risk of Breast Cancer.当代激素避孕与乳腺癌风险。
N Engl J Med. 2017 Dec 7;377(23):2228-2239. doi: 10.1056/NEJMoa1700732.
2
Epidemiology of Endometrial Carcinoma: Etiologic Importance of Hormonal and Metabolic Influences.子宫内膜癌的流行病学:激素和代谢影响的病因学重要性
Adv Exp Med Biol. 2017;943:3-46. doi: 10.1007/978-3-319-43139-0_1.
3
Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium.按组织学亚型分类的卵巢癌风险因素:来自卵巢癌队列联盟的分析
炔雌醇环丙孕酮片和二甲双胍对二氢睾酮诱导的大鼠子宫内膜损伤的治疗作用
Ann Transl Med. 2023 Mar 31;11(6):247. doi: 10.21037/atm-21-2441. Epub 2023 Feb 2.
4
Current role of Pipelle endometrial sampling in early diagnosis of endometrial cancer.Pipelle子宫内膜取样在子宫内膜癌早期诊断中的当前作用。
Transl Cancer Res. 2020 Dec;9(12):7716-7724. doi: 10.21037/tcr.2020.04.20.
5
Osthole suppresses the proliferation and induces apoptosis via inhibiting the PI3K/AKT signaling pathway of endometrial cancer JEC cells.蛇床子素通过抑制子宫内膜癌JEC细胞的PI3K/AKT信号通路来抑制其增殖并诱导凋亡。
Exp Ther Med. 2021 Oct;22(4):1171. doi: 10.3892/etm.2021.10605. Epub 2021 Aug 13.
6
Malignant Uterine Neoplasms Attended at a Brazilian Regional Hospital: 16-years Profile and Time Elapsed for Diagnosis and Treatment.巴西某地区医院收治的恶性子宫肿瘤:16 年的诊治情况及时间延迟分析。
Rev Bras Ginecol Obstet. 2021 Feb;43(2):137-144. doi: 10.1055/s-0040-1718434. Epub 2021 Jan 19.
J Clin Oncol. 2016 Aug 20;34(24):2888-98. doi: 10.1200/JCO.2016.66.8178. Epub 2016 Jun 20.
4
Revised Global Consensus Statement on Menopausal Hormone Therapy.《更年期激素治疗全球共识声明(修订版)》
Climacteric. 2016 Aug;19(4):313-5. doi: 10.1080/13697137.2016.1196047. Epub 2016 Jun 20.
5
Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies.子宫内膜癌与口服避孕药:36 项流行病学研究中 27276 例子宫内膜癌患者的个体参与者荟萃分析。
Lancet Oncol. 2015 Sep;16(9):1061-1070. doi: 10.1016/S1470-2045(15)00212-0. Epub 2015 Aug 4.
6
Adiposity and cancer risk: new mechanistic insights from epidemiology.肥胖与癌症风险:来自流行病学的新机制见解。
Nat Rev Cancer. 2015 Aug;15(8):484-98. doi: 10.1038/nrc3967.
7
Oral contraceptive use and colorectal cancer in the Nurses' Health Study I and II.护士健康研究I和II中口服避孕药的使用与结直肠癌
Cancer Epidemiol Biomarkers Prev. 2015 Aug;24(8):1214-21. doi: 10.1158/1055-9965.EPI-15-0172. Epub 2015 Jun 10.
8
An epidemiological model for prediction of endometrial cancer risk in Europe.用于预测欧洲子宫内膜癌风险的流行病学模型。
Eur J Epidemiol. 2016 Jan;31(1):51-60. doi: 10.1007/s10654-015-0030-9. Epub 2015 May 13.
9
Secular trends in menarcheal age in India-evidence from the Indian human development survey.印度初潮年龄的长期趋势——来自印度人类发展调查的证据
PLoS One. 2014 Nov 4;9(11):e111027. doi: 10.1371/journal.pone.0111027. eCollection 2014.
10
Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review.口服避孕药的使用与乳腺癌、宫颈癌、结直肠癌和子宫内膜癌的风险:系统评价。
Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):1931-43. doi: 10.1158/1055-9965.EPI-13-0298. Epub 2013 Sep 6.